Literature DB >> 17367582

Unified Huntington's disease rating scale: clinical practice and a critical approach.

Jirí Klempír1, Olga Klempírova, Natasa Spacková, Jana Zidovská, Jan Roth.   

Abstract

The purpose of this study was to test the usefulness of the Unified Huntington's Disease Rating Scale (UHDRS) in clinical practice. The UHDRS was used to examine 45 persons with genetically diagnosed Huntington's disease (HD) in various stages. The rate of motor involvement, cognitive deficit and reliance on nursing care rose in linear proportion to HD duration. The severity of motor involvement correlated significantly with all UHDRS subscales except for that of behavioral disorders, the rate of these disorders being unrelated to any of the parameters under study. The number of CAG triplets was inversely correlated with the age at onset of HD. Being considerably time consuming, administration of the whole UHDRS calls for interdisciplinary co-operation. For valid data acquisition, the participation of caregivers is also essential. In clinical practice it is advisable regularly to monitor the patient's conditions and the efficacy of treatment using the UHDRS motor, functional and behavioral subscales. Cognitive tests present difficulties but, in view of the progressive cognitive deterioration in HD, they are very useful in the early stage of the disease. The UHDRS does not assess impaired voluntary motor activity, or furnish information relating to therapy, dysphagia, weight loss, sexual problems or drug abuse.

Entities:  

Mesh:

Year:  2006        PMID: 17367582

Source DB:  PubMed          Journal:  Funct Neurol        ISSN: 0393-5264


  8 in total

Review 1.  Progress and prospects for genetic modification of nonhuman primate models in biomedical research.

Authors:  Anthony W S Chan
Journal:  ILAR J       Date:  2013

2.  Agreement between clinician-rated versus patient-reported outcomes in Huntington disease.

Authors:  Noelle E Carlozzi; Nicholas R Boileau; Joel S Perlmutter; Kelvin L Chou; Julie C Stout; Jane S Paulsen; Michael K McCormack; David Cella; Martha A Nance; Jin-Shei Lai; Praveen Dayalu
Journal:  J Neurol       Date:  2018-04-23       Impact factor: 4.849

3.  Clinical and genetic investigation of a Brazilian family with Huntington's disease.

Authors:  L A Agostinho; M Spitz; J S Pereira; C L A Paiva
Journal:  Funct Neurol       Date:  2016 Jul-Sep

4.  Assessment Scales for Patients with Advanced Huntington's Disease: Comparison of the UHDRS and UHDRS-FAP.

Authors:  Jessica Y Winder; Wilco P Achterberg; Johan Marinus; Sarah L Gardiner; Raymund A C Roos
Journal:  Mov Disord Clin Pract       Date:  2018-08-24

5.  Increased nuclear DNA damage precedes mitochondrial dysfunction in peripheral blood mononuclear cells from Huntington's disease patients.

Authors:  Georgina Askeland; Zaneta Dosoudilova; Marie Rodinova; Jiri Klempir; Irena Liskova; Anna Kuśnierczyk; Magnar Bjørås; Gaute Nesse; Arne Klungland; Hana Hansikova; Lars Eide
Journal:  Sci Rep       Date:  2018-06-29       Impact factor: 4.379

6.  Rating Scales and Performance-based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations.

Authors:  Tiago A Mestre; Monica Busse; Aileen M Davis; Lori Quinn; Filipe B Rodrigues; Jean-Marc Burgunder; Noelle E Carlozzi; Francis Walker; Aileen K Ho; Cristina Sampaio; Christopher G Goetz; Esther Cubo; Pablo Martinez-Martin; Glenn T Stebbins
Journal:  Mov Disord Clin Pract       Date:  2018-05-09

7.  A two years longitudinal study of a transgenic Huntington disease monkey.

Authors:  Anthony Ws Chan; Yan Xu; Jie Jiang; Tayeb Rahim; Dongming Zhao; Jannet Kocerha; Tim Chi; Sean Moran; Heidi Engelhardt; Katherine Larkin; Adam Neumann; Haiying Cheng; Chunxia Li; Katie Nelson; Heather Banta; Stuart M Zola; Francois Villinger; Jinjing Yang; Claudia M Testa; Hui Mao; Xiaodong Zhang; Jocelyne Bachevalier
Journal:  BMC Neurosci       Date:  2014-03-03       Impact factor: 3.288

8.  A Computational Cognitive Biomarker for Early-Stage Huntington's Disease.

Authors:  Thomas V Wiecki; Chrystalina A Antoniades; Alexander Stevenson; Christopher Kennard; Beth Borowsky; Gail Owen; Blair Leavitt; Raymund Roos; Alexandra Durr; Sarah J Tabrizi; Michael J Frank
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.